|
|
 |
|
Viewing report
|
|
|
|
Analysis of Cancer Immunotherapy: The World Guide
Bioseeker, Feb 2004
'Analysis of Cancer Immunotherapy: The World Guide' offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in cancer immunotherapy.
It is at the same time a map of the research and development, a history of the achievements up to date, and a guide pointing out the directions of the future.
This tool provides you with an immense amount of information structured and analyzed to assist you in your work.
Additionally, BioSeeker Group has developed a CD-ROM searchable database, which is highly updated to reflect the most recent advances in the field of cancer immunotherapy development, in order to help you perform your own analysis, go back to the source data for in-depth information, and present the research and development in tables and graphs suited for your own specific purposes.
A significant advantage with our CD-ROM searchable databases is that we provide you with well-structured information.
Each pipeline drug/project has been carefully defined and classified in categories and subcategories. The main categories include therapy type, effect, mechanism of action (molecular target), indication, stage of development etc. These categories are further organized and classified in sub-categories. In comparison with other available databases, the Group CD-ROM searchable databases gives better overview and specific search capabilities.
Our hope is that this product will assist you in your struggle of finding the right partners, optimizing your licensing deals, wisely choosing which projects give you the best competitive advantage, and assuring you that your decisions have been based on the most accurate, validated and precise facts available.
For your convenience, information about new innovative cancer therapies such as antisense, monoclonal antibodies, gene therapy, antigen- or cellular-based vaccines, liposomal hormones, apoptotic drugs and other small molecular drugs are analyzed in more than 100 extensive tables and graphs.
'Analysis of Cancer Immunotherapy - The World Guide' gives you easy-to-read tables with projects classified into well-defined structures based on type of therapy given, effect and mechanism. The graphs provide all the relations of these factors as well as the general and specific trends in the current cancer immunotherapy pipeline.
'Analysis of Cancer Immunotherapy: The World Guide' is based on three major parts
- Analysis
- Information structure
- Databases
Included in this advantageous package are several products already appreciated by many of our customers representing an immense value:
- A Shift in Cancer Immunotherapy Strategies?
- The Global Structure of Cancer Immunotherapy R&D
- Intellectual Property Analysis of Cancer Immunotherapy
- The World's Largest Cancer Immunotherapy Database
Get an analytical tool including:
- Information on close to 300 companies active in cancer immunotherapy
- Information on more than 400 clinical trials
- Information on more than 250 different therapeutic drugs/strategies
- 100 graphs illustrating the most important relations between types of therapy, effects and mechanisms
- Advanced analysis of general and specific trends in the pipeline
- Possibility of performing advanced searches suited to your individual needs
- Taking these searches a step further by generating specific and relevant tables and graphs for optimized support in your - decision-making process
- 6500 cancer immunotherapy related patents and applications
The concept of utilizing the immune system for the treatment of cancer has been tried for some time without any direct breakthrough success. So far 'passive' immunotherapy has experienced most success, with antibody and cytokine therapy leading the way.
One example is Rituxan, a drug that has seen its revenue grow from $152 million in 1998 to more than $1.4 billion in 2003. Other immune-based therapies that have already reached the market are Herceptin, Avastin, Zevailn, Bexxar, Campath and OncoVax.
Other cancer vaccine strategies that are on the way are Actimmune, Allovectin-7, Avicine, BEC2, Canvaxin, CeaVac, Gastrimmune, GMK, LymphoCide, Melacine, Ovarex, Oncophage and Osidem. These treatments are all FDA approved or in late stage clinical trails. Immunotherapy has for some time been heralded as a breakthrough approach for cancer treatment. Although the potential of this strategy remains solid, there are still a number if missing pieces. The efficacy of immunotherapy should and could be improved. More simple protocols are now being exchanged for more sophisticated ones, and novel solutions are continuing to emerge.
The report also evaluates the latest advancements in cancer immunotherapy as well as describes key company activities. BioSeeker Group is monitoring a large number of companies working in this field enabling highly updated analysis.
In a coming report entitled 'Immunotherapies Impact on the Cancer Market', BioSeeker Group will discuss late stage immunotherapy drugs and their effect on the market.
This report will assist you in:
1. Tracking cutting edge companies, therapies and new technologies
2. Rapid identification of partners & competitors
3. Laying down a comprehensive framework for further analysis of the field
4. Producing presentations surrounding the development of prostate cancer therapeutics
5. Identifying emerging prostate cancer products & key areas of pharmaceutical R&D
Some of the companies analyzed:
Abgenix, Active Biotech, Advanced Photonix, Inc. (Jenner Biotherapeutic), Agennix, AltaRex, Anosys, Antigenics, Antisoma/Abbott , AVAX Technologies, Aventis, AVI BioPharma, Bayer AG, Berlex Laboratories, Biogen, Biomira, BioStar/YM BioSciences , Biovector, Biovest International, Boehringer Ingelheim, CancerVax, Celgene, Cell Genesys, CellGenix, CellTech Group, CEL-SCI, Centocor /GSK, Chiron, Chugai Pharma., Coley Pharmaceuticals, Corixa, Dendreon, Enzon, Epimmune, Favrille, Genentech, Genitope, Genmab A/S, Genta, Genzyme, GlaxoSmithKline, GPC Biotech, Human Genome Sciences, IBC Pharmaceuticals , IDEC Pharma., Igeneon, ILEX Oncology, ImClone systems, Immunex, Immuno-Designed Molecules, ImmunoGen / British Biotech, Immunomedics, Intermune, Intracel, Johnson & Johnson, Kyowa Hakko, Lexigen Pharmaceuticals , Lifetime Pharmaceuticals, Ligand Pharmaceuticals, Maxim, Medarex, MedImmune, Merck, Micromet, ML Laboratories (Cobra Therapeutics)., Mologen Holding / Aventis, NeoPharm, NEXTherapeutics, Northwest Biotherapeutics, Onyvax, Oxford BioMedica, Oxxon Pharmaccines, Peregrine, Pharmexa A/S, Point Therapeutics, Progenics Pharma, Protein Design Labs , Richter Gedeon, Roche, Sanofi-Synthelabo , Schering AG, Schering-Plough, SciClone Pharmaceuticals, Seattle Genetics, Sumitomo Pharmaceuticals, Theratechnologies, Therion Biologics, Titan Pharmaceuticals, Tragen, Transgene, Valentis, Vasogen, Vical, Viragen, Viventia Biotech, Wilex AG, Wyeth Pharmaceuticals, Xcyte, YM Biosciences, Zycos
Customers who bought this item also bought
Immunotherapy in Oncology: Gaining Momentum
The World Cancer Market Yearbook 2005
Cancer: Immunotherapy Beyond Monoclonals
Chinese Markets for Cancer Treatment Drugs
Cancer Vaccines Fantasy or Future?
Drug Delivery in Cancer - Technologies, Markets and Companies
The Asian Cancer Market Outlook to 2010
New Concepts in Cancer Therapeutics
|
|
|
|
